Published on March 19, 2010 at 12:49 AM
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage
oncology and dermatology biopharmaceutical company, announced today that
data from its Phase 2 study of PV-10 for metastatic melanoma has been
accepted for presentation at the 2010 American Society of Clinical
Oncology (ASCO) Scientific Program to be held on June 4 – 8, 2010 in
Chicago, Illinois.
“Chemoablation of metastatic
melanoma with rose bengal (PV-10)”
Dr. Sanjiv Agarwala, Chief, Medical Oncology and Hematology at St.
Luke’s Hospital and Health Network in Bethlehem, PA, and Principal
Investigator for Provectus’s Phase 2 PV-10 trial site at St. Luke’s,
will present Abstract #8534, entitled “Chemoablation of metastatic
melanoma with rose bengal (PV-10),” in the General Poster Session.
Dr. Agarwala said, “With enrollment of all 80 subjects this multi-center
Phase 2 trial completed in May 2009, I look forward to presenting a
comprehensive update on PV-10 for treatment of metastatic melanoma. As I
recently noted, PV-10 is intriguing to me as an oncologist because it
appears to recruit immune cells to the ablation site, leading to the
potential of a systemic benefit.”
Craig Dees, PhD, CEO of Provectus said, “We look forward to Dr.
Agarwala’s presentation, which marks another milestone for the continued
research and development of PV-10 as we gain more momentum in our fight
against cancer. Metastatic melanoma is a dreadful and deadly disease,
and we believe PV-10 holds promise as a viable, safe and effective
treatment, with minimal side effects, not only for this disease, but
potentially for a broad spectrum of other cancers as well.”
Source Provectus Pharmaceuticals, Inc. (www.pvct.com)
b99828d4-16e8-4ed2-aff8-b79660896935|0|.0
Posted in: Drug Trial News | Medical Condition News
Tags: Apoptosis, Atopic Dermatitis, Breast Cancer, Cancer, Cell, Dermatitis, Dermatology, Hematology, Hospital, Liver Cancer, Melanoma, Oncology, Psoriasis